These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 31028999)
1. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression. Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner. Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364 [TBL] [Abstract][Full Text] [Related]
3. HCP5 contributes to cisplatin resistance in gastric cancer through miR-128/HMGA2 axis. Liang L; Kang H; Jia J Cell Cycle; 2021 Jun; 20(11):1080-1090. PubMed ID: 33993846 [TBL] [Abstract][Full Text] [Related]
4. Long non‑coding RNA HAND2‑AS1/miR‑106a/PTEN axis re‑sensitizes cisplatin‑resistant ovarian cells to cisplatin treatment. Li L; Li L; Hu L; Li T; Xie D; Liu X Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34476500 [TBL] [Abstract][Full Text] [Related]
5. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Cheng C; Qin Y; Zhi Q; Wang J; Qin C Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815 [TBL] [Abstract][Full Text] [Related]
6. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2. He R; Liu H Gene; 2020 Jul; 747():144553. PubMed ID: 32165307 [TBL] [Abstract][Full Text] [Related]
7. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Yi D; Xu L; Wang R; Lu X; Sang J Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043 [TBL] [Abstract][Full Text] [Related]
8. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis. Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833 [TBL] [Abstract][Full Text] [Related]
9. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells. Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Zhang XW; Bu P; Liu L; Zhang XZ; Li J Biochem Biophys Res Commun; 2015 Jul; 462(3):227-32. PubMed ID: 25956062 [TBL] [Abstract][Full Text] [Related]
12. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Wang L; Luan T; Zhou S; Lin J; Yang Y; Liu W; Tong X; Jiang W Cancer Med; 2019 Aug; 8(9):4389-4403. PubMed ID: 31215169 [TBL] [Abstract][Full Text] [Related]
13. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis. Song X; Wang X; Chen X; Yu Z; Zhou Y J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194 [TBL] [Abstract][Full Text] [Related]
14. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480 [TBL] [Abstract][Full Text] [Related]
15. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT. Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359 [TBL] [Abstract][Full Text] [Related]
17. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Gao C; Yuan X; Jiang Z; Gan D; Ding L; Sun Y; Zhou J; Xu L; Liu Y; Wang G Breast Cancer Res Treat; 2019 Jul; 176(2):291-301. PubMed ID: 31006103 [TBL] [Abstract][Full Text] [Related]
18. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer. Yan H; Luo B; Wu X; Guan F; Yu X; Zhao L; Ke X; Wu J; Yuan J Int J Biol Sci; 2021; 17(10):2606-2621. PubMed ID: 34326697 [TBL] [Abstract][Full Text] [Related]
20. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]